Poseida Therapeutics, Inc. (PSTX)
Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs.
The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in Phase I trial for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC).
It is also developing P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; and P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, ovarian, and other epithelial-derived cancers.
In addition, the company engages in the development of P-CD19CD20-ALLO1 for B cell malignancies and other autoimmune diseases; and P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for multiple myeloma.
Further, it is developing P-PSMA-ALLO1, an allogeneic CAR-T product candidate for treating mCRPC. Additionally, the company engages in the development of P-OTC-101 and P-FVIII-101 that are clinical stage liver-directed gene therapies; and other allogeneic dual CAR candidates.
It has a research collaboration and license agreement with Takeda Pharmaceutical Company Limited. The company was incorporated in 2014 and is headquartered in San Diego, California.
|IPO Date||Jul 10, 2020|
9390 Towne Centre Drive
San Diego, California 92121
|Phone||858 779 3100|
|Fiscal Year||January - December|
|Reporting Currency||US Dollars|
|Dr. Eric M. Ostertag M.D., Ph.D.||Executive Chairman|
|Mark J. Gergen J.D.||Chief Executive Officer and Director|
|Johanna M. Mylet CPA||Chief Financial Officer|
|Kerry D. Ingalls||Chief Operating Officer|
|Kristin Martin||Chief People and Administrative Officer|
|Sarah Thailing||Senior Director of Corporate Communications and IR|
|Harry J. Leonhardt Esq., J.D.||General Counsel, Chief Compliance Officer and Corporate Secretary|
|Dr. Devon J. Shedlock Ph.D.||Chief Scientific Officer of Cell Therapies|
|Lisa Portale||Senior Vice President of Regulatory Affairs|
|Brent Warner||President of Gene Therapy|
Latest SEC Filings
|May 18, 2022||3||Initial statement of beneficial ownership of securities|
|May 18, 2022||8-K||Current report|
|May 12, 2022||10-Q||Quarterly report [Sections 13 or 15(d)]|
|May 12, 2022||8-K||Current report|
|Apr 27, 2022||DEFA14A||Additional definitive proxy soliciting materials and Rule 14(a)(12) material|
|Apr 27, 2022||DEF 14A||Other definitive proxy statements|
|Apr 25, 2022||SC 13D/A||General statement of acquisition of beneficial ownership|
|Apr 7, 2022||8-K||Current report|
|Mar 18, 2022||4||Statement of changes in beneficial ownership of securities|
|Mar 10, 2022||10-K||Annual report [Section 13 and 15(d), not S-K Item 405]|
|View All SEC Filings|